NU SKIN ENTERPRISES INC - A (NUS) Stock Fundamental Analysis

NYSE:NUS • US67018T1051

8.5 USD
-0.07 (-0.82%)
Last: Feb 27, 2026, 02:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to NUS. NUS was compared to 36 industry peers in the Personal Care Products industry. Both the profitability and the financial health of NUS get a neutral evaluation. Nothing too spectacular is happening here. NUS has a bad growth rate and is valued cheaply.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year NUS was profitable.
  • NUS had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: NUS reported negative net income in multiple years.
  • NUS had a positive operating cash flow in 4 of the past 5 years.
NUS Yearly Net Income VS EBIT VS OCF VS FCFNUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 7.69%, NUS is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
  • NUS's Return On Equity of 13.70% is amongst the best of the industry. NUS outperforms 80.56% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 4.08%, NUS is in line with its industry, outperforming 55.56% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for NUS is significantly below the industry average of 10.65%.
Industry RankSector Rank
ROA 7.69%
ROE 13.7%
ROIC 4.08%
ROA(3y)-1.25%
ROA(5y)2.75%
ROE(3y)-3.26%
ROE(5y)5.55%
ROIC(3y)5.22%
ROIC(5y)9.29%
NUS Yearly ROA, ROE, ROICNUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

  • With a decent Profit Margin value of 7.02%, NUS is doing good in the industry, outperforming 75.00% of the companies in the same industry.
  • The Operating Margin of NUS (3.87%) is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of NUS has declined.
  • NUS has a Gross Margin (67.20%) which is in line with its industry peers.
  • NUS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 3.87%
PM (TTM) 7.02%
GM 67.2%
OM growth 3Y-34.86%
OM growth 5Y-23.31%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.08%
GM growth 5Y-2.13%
NUS Yearly Profit, Operating, Gross MarginsNUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NUS is destroying value.
  • NUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NUS Yearly Shares OutstandingNUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
NUS Yearly Total Debt VS Total AssetsNUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 3.70 indicates that NUS is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of NUS (3.70) is better than 77.78% of its industry peers.
  • NUS has a debt to FCF ratio of 4.29. This is a neutral value as NUS would need 4.29 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 4.29, NUS is doing good in the industry, outperforming 77.78% of the companies in the same industry.
  • A Debt/Equity ratio of 0.26 indicates that NUS is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.26, NUS is doing good in the industry, outperforming 61.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 4.29
Altman-Z 3.7
ROIC/WACC0.5
WACC8.22%
NUS Yearly LT Debt VS Equity VS FCFNUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.3 Liquidity

  • NUS has a Current Ratio of 2.15. This indicates that NUS is financially healthy and has no problem in meeting its short term obligations.
  • NUS's Current ratio of 2.15 is in line compared to the rest of the industry. NUS outperforms 52.78% of its industry peers.
  • NUS has a Quick Ratio of 1.45. This is a normal value and indicates that NUS is financially healthy and should not expect problems in meeting its short term obligations.
  • NUS has a Quick ratio (1.45) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.45
NUS Yearly Current Assets VS Current LiabilitesNUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 51.76% over the past year.
  • The earnings per share for NUS have been decreasing by -18.78% on average. This is quite bad
EPS 1Y (TTM)51.76%
EPS 3Y-23.58%
EPS 5Y-18.78%
EPS Q2Q%-23.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-16.89%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue is expected to grow by 1.05% on average over the next years.
EPS Next Y11.18%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-4.69%
Revenue Next 2Y1.05%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
NUS Yearly Revenue VS EstimatesNUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B 2.5B
NUS Yearly EPS VS EstimatesNUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 6.59, the valuation of NUS can be described as very cheap.
  • 91.67% of the companies in the same industry are more expensive than NUS, based on the Price/Earnings ratio.
  • NUS is valuated cheaply when we compare the Price/Earnings ratio to 27.11, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 5.93, the valuation of NUS can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, NUS is valued cheaply inside the industry as 88.89% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of NUS to the average of the S&P500 Index (28.13), we can say NUS is valued rather cheaply.
Industry RankSector Rank
PE 6.59
Fwd PE 5.93
NUS Price Earnings VS Forward Price EarningsNUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NUS is valued cheaper than 100.00% of the companies in the same industry.
  • NUS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NUS is cheaper than 88.89% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.77
EV/EBITDA 3.4
NUS Per share dataNUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • NUS has a Yearly Dividend Yield of 2.77%.
  • NUS's Dividend Yield is a higher than the industry average which is at 1.61.
  • Compared to an average S&P500 Dividend Yield of 1.80, NUS pays a better dividend.
Industry RankSector Rank
Dividend Yield 2.77%

5.2 History

  • The dividend of NUS decreases each year by -30.50%.
  • NUS has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-30.5%
Div Incr Years0
Div Non Decr Years0
NUS Yearly Dividends per shareNUS Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5

5.3 Sustainability

  • NUS pays out 10.87% of its income as dividend. This is a sustainable payout ratio.
DP10.87%
EPS Next 2YN/A
EPS Next 3YN/A
NUS Yearly Income VS Free CF VS DividendNUS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M
NUS Dividend Payout.NUS Dividend Payout, showing the Payout Ratio.NUS Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

NU SKIN ENTERPRISES INC - A

NYSE:NUS (2/27/2026, 2:03:40 PM)

8.5

-0.07 (-0.82%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)02-12
Earnings (Next)05-06
Inst Owners77.1%
Inst Owner Change1.1%
Ins Owners2.11%
Ins Owner Change11.64%
Market Cap414.38M
Revenue(TTM)N/A
Net Income(TTM)109.61M
Analysts45
Price TargetN/A
Short Float %3.7%
Short Ratio3.64
Dividend
Industry RankSector Rank
Dividend Yield 2.77%
Yearly Dividend0.24
Dividend Growth(5Y)-30.5%
DP10.87%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-27
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)42.99%
Min EPS beat(2)12.21%
Max EPS beat(2)73.77%
EPS beat(4)4
Avg EPS beat(4)59.11%
Min EPS beat(4)12.21%
Max EPS beat(4)76.64%
EPS beat(8)7
Avg EPS beat(8)43.78%
EPS beat(12)10
Avg EPS beat(12)34.6%
EPS beat(16)13
Avg EPS beat(16)24.83%
Revenue beat(2)1
Avg Revenue beat(2)-1.07%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)1.5%
Revenue beat(4)3
Avg Revenue beat(4)0.39%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)2.51%
Revenue beat(8)5
Avg Revenue beat(8)-0.35%
Revenue beat(12)5
Avg Revenue beat(12)-1.28%
Revenue beat(16)7
Avg Revenue beat(16)-1.32%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)3.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.24%
Valuation
Industry RankSector Rank
PE 6.59
Fwd PE 5.93
P/S 0.27
P/FCF 7.77
P/OCF 4.63
P/B 0.52
P/tB 0.62
EV/EBITDA 3.4
EPS(TTM)1.29
EY15.18%
EPS(NY)1.43
Fwd EY16.87%
FCF(TTM)1.09
FCFY12.87%
OCF(TTM)1.83
OCFY21.59%
SpS32.01
BVpS16.41
TBVpS13.78
PEG (NY)0.59
PEG (5Y)N/A
Graham Number21.82
Profitability
Industry RankSector Rank
ROA 7.69%
ROE 13.7%
ROCE 5.16%
ROIC 4.08%
ROICexc 5.21%
ROICexgc 6.05%
OM 3.87%
PM (TTM) 7.02%
GM 67.2%
FCFM 3.42%
ROA(3y)-1.25%
ROA(5y)2.75%
ROE(3y)-3.26%
ROE(5y)5.55%
ROIC(3y)5.22%
ROIC(5y)9.29%
ROICexc(3y)6.41%
ROICexc(5y)12.52%
ROICexgc(3y)8.32%
ROICexgc(5y)17.24%
ROCE(3y)6.61%
ROCE(5y)11.76%
ROICexgc growth 3Y-45.58%
ROICexgc growth 5Y-28.67%
ROICexc growth 3Y-42.83%
ROICexc growth 5Y-26.9%
OM growth 3Y-34.86%
OM growth 5Y-23.31%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.08%
GM growth 5Y-2.13%
F-Score6
Asset Turnover1.1
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 4.29
Debt/EBITDA 1.8
Cap/Depr 64.7%
Cap/Sales 2.31%
Interest Coverage 250
Cash Conversion 76.96%
Profit Quality 48.67%
Current Ratio 2.15
Quick Ratio 1.45
Altman-Z 3.7
F-Score6
WACC8.22%
ROIC/WACC0.5
Cap/Depr(3y)74.52%
Cap/Depr(5y)79.94%
Cap/Sales(3y)2.68%
Cap/Sales(5y)2.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.76%
EPS 3Y-23.58%
EPS 5Y-18.78%
EPS Q2Q%-23.68%
EPS Next Y11.18%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-16.89%
Revenue Next Year-4.69%
Revenue Next 2Y1.05%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.1%
EBIT growth 3Y-43.79%
EBIT growth 5Y-28.27%
EBIT Next Year155.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.66%
FCF growth 3Y-1.31%
FCF growth 5Y-8.9%
OCF growth 1Y-0.72%
OCF growth 3Y-7.59%
OCF growth 5Y-8.88%

NU SKIN ENTERPRISES INC - A / NUS FAQ

Can you provide the ChartMill fundamental rating for NU SKIN ENTERPRISES INC - A?

ChartMill assigns a fundamental rating of 5 / 10 to NUS.


What is the valuation status of NU SKIN ENTERPRISES INC - A (NUS) stock?

ChartMill assigns a valuation rating of 8 / 10 to NU SKIN ENTERPRISES INC - A (NUS). This can be considered as Undervalued.


How profitable is NU SKIN ENTERPRISES INC - A (NUS) stock?

NU SKIN ENTERPRISES INC - A (NUS) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for NUS stock?

The Price/Earnings (PE) ratio for NU SKIN ENTERPRISES INC - A (NUS) is 6.59 and the Price/Book (PB) ratio is 0.52.


Can you provide the dividend sustainability for NUS stock?

The dividend rating of NU SKIN ENTERPRISES INC - A (NUS) is 5 / 10 and the dividend payout ratio is 10.87%.